News coverage about Coherus BioSciences (NASDAQ:CHRS) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Coherus BioSciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.1915585351815 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of Coherus BioSciences (NASDAQ:CHRS) traded up 3.60% during trading on Monday, reaching $11.50. 537,602 shares of the company traded hands. The firm’s market capitalization is $590.48 million. Coherus BioSciences has a 12 month low of $10.65 and a 12 month high of $30.43. The firm has a 50-day moving average price of $13.17 and a 200-day moving average price of $15.68.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.21. The business had revenue of $1.40 million during the quarter. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. Equities research analysts anticipate that Coherus BioSciences will post ($5.13) EPS for the current year.

Several equities analysts recently commented on CHRS shares. BidaskClub lowered shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Tuesday, August 15th. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $25.00 price target (down previously from $32.00) on shares of Coherus BioSciences in a research report on Tuesday, August 8th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $17.00 price target (down previously from $24.00) on shares of Coherus BioSciences in a research report on Wednesday, September 27th. Three equities research analysts have rated the stock with a sell rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $32.00.

WARNING: “Coherus BioSciences (CHRS) Receives Media Impact Rating of 0.14” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at

In related news, insider Alan C. Herman sold 17,535 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total transaction of $263,375.70. Following the completion of the sale, the insider now directly owns 49,651 shares in the company, valued at $745,758.02. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 26.28% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.